Vasoactive Peptides in Portal Pressure

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2005 by Bayside Health.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Bayside Health
ClinicalTrials.gov Identifier:
NCT00163982
First received: September 13, 2005
Last updated: July 25, 2007
Last verified: September 2005

September 13, 2005
July 25, 2007
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00163982 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Vasoactive Peptides in Portal Pressure
Not Provided

This study is looking at the detection of vasoactive peptides in portal hypertension.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Portal Hypertension
Drug: Norfloxacin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • HVPG >= 12 mmHg
Both
18 Years to 75 Years
Not Provided
Contact: William W Kemp, MBBS, FRACP 92762000 ext 3327 w.kemp@alfred.org.au
Australia
 
NCT00163982
AH4204
Not Provided
Not Provided
Bayside Health
Not Provided
Principal Investigator: William W Kemp, MBBS, FRACP The Alfred
Bayside Health
September 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP